Loading JYL Briefings...

AI & Tech Life Sciences About Jae Subscribe

Archive

All briefings and reviews.

The public archive is limited to the two briefing franchises. Draft distribution formats stay in the internal outreach workspace.

AI & Tech Weeklies Life Sciences / Regulatory Weeklies AI & Tech Quarterly Reviews Life Sciences / Regulatory Quarterly Reviews

Weekly Briefs

AI & Tech Weeklies

AUG 2026W32Aug 3 - Aug 9The containment story stopped being about one lab's bad week and became an industry-wide admission that evaluation environments are now attack surface — and that the next model may cross the line the frameworks were w...Weekly Brief · 20 min read JUL 2026W31Jul 27 - Aug 2The frontier spent this week auditing itself in public — two labs published containment failures, two open letters fought over what to do about it, and the price of intelligence fell again on work the model did itself.Weekly Brief · 25 min read W30Jul 20 - Jul 26Frontier capability got cheaper on every axis this week, while the two things that actually gate deployment — containment and clinical evidence — did not move at all.Weekly Brief · 24 min read W29Jul 13 - Jul 19AI stopped merely writing code this week and started designing biology's tools, rebuilding its own product surface, and testing how much filesystem trust builders will extend to an agent.Weekly Brief · 14 min read W28Jul 6 - Jul 12The frontier moved on performance per dollar this week: OpenAI reset the flagship baseline while the open-model stack simultaneously got cheaper to run and closer to being regulated out of the top tier.Weekly Brief · 13 min read JUN 2026W27Jun 29 - Jul 5Government-gated frontier access hardened into process this week — export controls lifted, a limited preview granted, and a standing pre-release testing framework reportedly in advanced talks — while Anthropic and NVI...Weekly Brief · 13 min read W26Jun 22 - Jun 28The frontier's scarce input shifted again this week — from raw capability to who is allowed to use it, what silicon it runs on, and how the price ladder is structured — as the White House gated a commercial model roll...Weekly Brief · 15 min read W25Jun 15 - Jun 21The frontier moved from a capability race into a governance and access race this week — a US government directive yanked two shipped Anthropic models, the field's most decorated structural-biology researcher switched...Weekly Brief · 13 min read W24Jun 8 - Jun 14The most capable publicly available model shipped on Monday and was switched off by the US government on Friday — the rest of the week was infrastructure quietly repricing around agents.Weekly Brief · 15 min read W23Jun 1 - Jun 7Anthropic ran the week: it opened a sector-specific application pathway to its most capable model, shipped the agent infrastructure that makes that model deployable in regulated environments, and published internal da...Weekly Brief · 14 min read MAY 2026W22May 25 - May 31The week's signal was the AI infrastructure stack repricing at sovereign scale — a frontier model GA bundled with a $65B private round, a standalone coding agent posting nine-figure ARR, and the serving layer beneath...Weekly Brief · 15 min read W21May 18 - May 24The week's signal was AI agents entering regulated, domain-specific work — not as demos, but as tools that shipped lab-credible outputs, survived a one-month build constraint, and reached alpha with a plugin architect...Weekly Brief · 17 min read W20May 11 - May 17The week's pattern was deployment posture: where frontier capability gets pointed, who gets a preview, and what hardware sits underneath. Anthropic committed $200M to the Gates Foundation to put Claude inside disease...Weekly Brief · 20 min read W19May 4 - May 10The week's pattern was distribution and substrate, not capability. Anthropic stacked three compute suppliers and a PE-backed integration arm in seven days; OpenAI shipped a default-model swap, a domain-gated cyber tie...Weekly Brief · 21 min read APR 2026W18Apr 27 - May 3The week's frontier moves were structural, not incremental: Microsoft and OpenAI rewrote the contract that defined the modern AI distribution stack, GPT-5.5's bio bug bounty testing window opened the same week first-w...Weekly Brief · 18 min read W17Apr 20 - Apr 26The frontier shipped four products in seven days, the runner-up shipped a model and a postmortem and a 5-gigawatt power deal, the open-weight tier dropped 1.6 trillion parameters at sub-$2 per million tokens, and the...Weekly Brief · 21 min read W16Apr 13 - Apr 19Anthropic spent the week advancing its life-sciences playbook on three simultaneous layers — model, product, governance — while AWS quietly shipped the compliance primitive that regulated-industry builders have been w...Weekly Brief · 17 min read W15Apr 6 - Apr 12Frontier AI moved up the value chain this week — gating capability, owning biology, codifying orchestration, hosting weights, and shipping inference to the device. The Mythos cyber benchmark figures are the highest-si...Weekly Brief · 16 min read MAR 2026W14Mar 30 - Apr 5The open-model race hit a new gear with Gemma 4, Anthropic officially acknowledged Mythos and announced a limited access program, rewrote its safety framework, and OpenAI formally closed its largest financing round. E...Weekly Brief · 11 min read W13Mar 23 - Mar 29Anthropic shipped a confirmed product triple and had a model and IPO timeline leak in the same week — a combination of verified engineering releases and press-reported speculation that should be read separately.Weekly Brief · 8 min read W12Mar 16 - Mar 22The coding-agent stack is consolidating fast: a non-frontier-lab model can now compete on agentic benchmarks, the leading lab is vertically integrating dev tooling via acquisition, and the White House wants to preempt...Weekly Brief · 8 min read W11Mar 9 - Mar 15The inference stack is consolidating from silicon to software while the governance stack barely exists — and both facts landed in the same seven-day window.Weekly Brief · 10 min read W10Mar 2 - Mar 8The week GPT-5.4 shipped computer use that exceeded human performance on one desktop benchmark, the U.S. government blacklisted its most safety-conscious AI lab, and the entire inference stack raced to support hybrid...Weekly Brief · 11 min read FEB 2026W09Feb 23 - Mar 1Three frontier labs dropped major model upgrades in four days, OpenAI drew its first public safety line on a deployed coding model, and the enterprise deployment channel locked in with the big-four consultancies — the...Weekly Brief · 11 min read W08Feb 16 - Feb 22Seven major model releases hit in February alone — but W08 is the one that mattered: Anthropic and Google both shipped flagship-class intelligence at mid-tier pricing, xAI shipped native multi-agent orchestration, and...Weekly Brief · 11 min read W07Feb 9 - Feb 15The week of Feb 9-15 crystallized two concurrent stories: the US-China AI conflict escalated from a technical dispute to a congressional geopolitical event, while the enterprise agentic platform race opened with OpenA...Weekly Brief · 9 min read W06Feb 2 - Feb 8Agentic coding became the primary competitive arena in AI this week: Anthropic and OpenAI shipped flagship models within minutes of each other on February 5, xAI's Grok Imagine 1.0 claimed the 1 video leaderboard slot...Weekly Brief · 9 min read JAN 2026W05Jan 26 - Feb 1DeepSeek R1's January 2025 release detonated the inference-cost assumption undergirding U.S. AI dominance — the same week frontier labs raced to ship agents everywhere, showing that efficiency and deployment velocity...Weekly Brief · 8 min read W04Jan 19 - Jan 25The week of Jan 19–25 was defined by alignment and governance moves at Anthropic and OpenAI, Google shipping its first real personal-context layer, and an escalating legal threat to OpenAI's corporate structure — all...Weekly Brief · 10 min read W03Jan 12 - Jan 18Agentic infrastructure locked in this week: DeepSeek's January 2025 release still framed the frontier-cost debate, Google rewired the commerce stack for AI agents, and Apple handed Gemini 2 billion endpoints.Weekly Brief · 7 min read W02Jan 5 - Jan 11CES 2026 set the hardware ceiling for the AI era: NVIDIA confirmed Rubin in production at 10x lower inference cost while Meta was reported to be paying $2-3B for execution-agent capability — together signaling that th...Weekly Brief · 9 min read DEC 2026W01Dec 29 - Jan 4The first week of 2026 established the year's defining tension: an open-source Chinese model matched US frontier performance at a fraction of the cost, while US incumbents responded by locking in capital, acquiring ag...Weekly Brief · 9 min read

Weekly Briefs

Life Sciences / Regulatory Weeklies

AUG 2026W32Aug 3 - Aug 9A narrow week, and the narrowness is the signal: almost nothing shipped, and what did ship was all about how a claim gets proven rather than what got approved. FDA put the highest-profile multi-cancer screening test i...Weekly Brief · 22 min read JUL 2026W31Jul 27 - Aug 2Two regulators worked the same question this week — how much structure to put around AI that touches a patient — and answered it in opposite registers. MHRA built routes in: a live-deployment sandbox with an open appl...Weekly Brief · 28 min read W30Jul 20 - Jul 26A quiet week for pathway news, and the sharpest document of it came from outside the regulatory system: an independent evaluation putting a launched consumer AI health-triage product at roughly coin-flip agreement wit...Weekly Brief · 25 min read W29Jul 13 - Jul 19The week's throughline was where the regulated boundary sits for AI in care — and four parties spent it arguing from four directions: a regulator drafting the on-ramp, a legislature wiring AI into payment denial, clou...Weekly Brief · 13 min read W28Jul 6 - Jul 12The week's throughline was regulators writing the rulebook for AI-enabled devices ahead of the products — a cross-jurisdiction lifecycle framework closing consultation, a dated EU disclosure obligation that secondary...Weekly Brief · 13 min read JUN 2026W27Jun 29 - Jul 5The week's throughline was the gap between capability and clearance: a research tool that ships with auditable artifacts but no regulatory framing, a device that becomes the first patient-facing LLM to clear FDA, a jo...Weekly Brief · 14 min read W26Jun 22 - Jun 28The evidence bar for clinical AI rose this week — not from a regulator, but from the journals regulators and procurement committees cite, while capital and Congress redrew the map underneath it.Weekly Brief · 15 min read W25Jun 15 - Jun 21The week's signal: capability is racing ahead of clearance — from a consumer imaging device launched outside the 510(k) gate to general-purpose LLMs beating purpose-built clinical tools, while the FDA itself loosens t...Weekly Brief · 13 min read W24Jun 8 - Jun 14The week's signal: the general-purpose model beat the purpose-built clinical tool on every axis, capital and validation arguments split in opposite directions, and review-process integrity became the variable founders...Weekly Brief · 14 min read W23Jun 1 - Jun 7The week's signal clustered on one move: regulators and builders both started treating AI as qualified evidence infrastructure — a toxicology predictor entering FDA's tool pipeline, an audited LLM clearing a national...Weekly Brief · 16 min read MAY 2026W22May 25 - May 31The week's signal: computational evidence moved from supplement to pathway-grade. A protein-biology world model shipped under MIT license with lab-confirmed binders, FDA put organoids, microphysiological systems, and...Weekly Brief · 17 min read W21May 18 - May 24Computational drug design crossed a generalization threshold, agentic AI absorbed thirty life-science databases into one query surface, the UK proposed collapsing trial and marketing authorization into a single instru...Weekly Brief · 18 min read W20May 11 - May 17The inspection clock compressed, the UK device map redrew, a frontier multimodal diagnostic AI cleared peer review, the first BCL-2 inhibitor landed in mantle cell lymphoma on a triple-expedited stack, the 30-year FDA...Weekly Brief · 24 min read W19May 4 - May 10A new clinical modality cleared, the regulator's review stack went AI-augmented, the post-approval coverage gap collapsed, a top-5 pharma signed itself wall-to-wall to a frontier model vendor, and a state medical boar...Weekly Brief · 18 min read APR 2026W18Apr 27 - May 3The trial-data pipeline, the regulator's own org chart, and the implementation layer all moved this week — FDA collapsed batch-mode trial submission into continuous streaming with two named sponsors live, MHRA hired i...Weekly Brief · 16 min read W17Apr 20 - Apr 26The federal regulatory stack moved from talking about AI and access to enforcing them — pricing the cost of overreliance, compressing the timeline from authorization to coverage, and re-drawing the line between AI-ass...Weekly Brief · 22 min read W16Apr 13 - Apr 19The regulatory ceiling hardened on both sides of the Atlantic this week — and three frontier-AI vendors (Anthropic, OpenAI, AWS) each shipped their own biopharma-specific move in the same 48-hour window. The vendor-ev...Weekly Brief · 24 min read W15Apr 6 - Apr 12Five distinct regulatory and evidence surfaces shifted this week. Two are official pathway or regulatory actions (MHRA olezarsen approval and aligned pathway; FDA DHT RFI). Three are evidence-surface shifts (clinical-...Weekly Brief · 13 min read MAR 2026W14Mar 30 - Apr 5This week had one confirmed regulatory action (UK MHRA clinical trial timing reform), one strong peer-reviewed science cluster (drug delivery papers), and two preprint-stage signals (DFNZ opioid pharmacology and Speci...Weekly Brief · 12 min read W13Mar 23 - Mar 29Japan broke new ground by conditionally approving the world's first two iPSC-derived cell therapies, while the FDA approved the first gene therapy for LAD-I, the MHRA overhauled its approval timeline, and Lilly placed...Weekly Brief · 11 min read W12Mar 16 - Mar 22The FDA approved two first-in-class drugs in the same week — an oral IL-23 blocker for psoriasis and the first treatment for PBC-related itch — while two Nature papers converged on multi-organ axes for neurodegenerati...Weekly Brief · 8 min read W11Mar 9 - Mar 15The week's biggest signal is that AI-discovered drugs are generating real clinical data — and the regulatory system is simultaneously inventing new approval pathways to handle what comes next.Weekly Brief · 8 min read W10Mar 2 - Mar 8A Science paper reported a CD70-HIT CAR-T signal against "hidden" antigen expression that conventional assays miss, DeepMind's diagnostic AI posted 90% accuracy in a real primary care clinic, the FDA announced it will...Weekly Brief · 12 min read FEB 2026W09Feb 23 - Mar 1February's regulatory baseline still defined the March window: QMSR compliance had just gone mandatory, FDA had already cleared the first AI tool that simultaneously detects and characterizes lung cancer on CT, and gu...Weekly Brief · 12 min read W08Feb 16 - Feb 22The February 16-22 window captured the week the FDA's quality system changed and the major AI labs raced to add medical features without regulatory infrastructure — QMSR went live on February 2, the cybersecurity prem...Weekly Brief · 12 min read W07Feb 9 - Feb 15The February 9-15 window arrived one week after the most consequential device quality regulatory shift in three decades — QMSR's February 2 effective date — while the EMA-FDA joint AI principles published in January m...Weekly Brief · 12 min read W06Feb 2 - Feb 8The most significant regulatory infrastructure shift in 30 years hit enforcement this week: FDA's QMSR replaced the 1996 QSR on February 2, and FDA issued QMSR-aligned cybersecurity premarket guidance the very next da...Weekly Brief · 11 min read JAN 2026W05Jan 26 - Feb 1The late-January to early-February regulatory stack rewired itself across a window boundary: QMSR took effect Feb 2 replacing the inspection paradigm, the FDA deregulated swaths of CDS and wearable oversight, launched...Weekly Brief · 11 min read W04Jan 19 - Jan 25The FDA executed a coordinated January package across adjacent windows — W01 (Jan 6: CDS and General Wellness final guidances), W01 (Jan 14: FDA x EMA joint AI-in-drug-development principles), and now (W04: cleared de...Weekly Brief · 12 min read W03Jan 12 - Jan 18FDA deregulated two categories of AI health software simultaneously while opening a new limited review pathway for chronic disease digital health — the largest shift in the digital health regulatory posture in recent...Weekly Brief · 9 min read W02Jan 5 - Jan 11FDA opened 2026 with its largest digital health deregulation in a decade — revising CDS and general wellness guidance to remove premarket review from single-recommendation tools and non-invasive wearable monitoring —...Weekly Brief · 11 min read DEC 2026W01Dec 29 - Jan 4The opening January window of 2026 produced the most significant regulatory signal in recent memory: FDA and EMA issued their first joint AI principles for drug development, creating a transatlantic compliance baselin...Weekly Brief · 10 min read

Quarterly Reviews

AI & Tech Quarterly Reviews

2026Q22026 Q2The binding constraint on frontier AI stopped being capability and became permission: by quarter close, two separate labs had their newest models placed under direct government access control — a US export-control dir...Quarterly Review · 13 min read Q12026 Q1Q1 2026 saw reasoning models commoditize (DeepSeek R1 matching o1 at 96% lower cost under MIT license) while computer-use agents crossed human parity (GPT-5.4 at 75% on OSWorld vs 72.4% human baseline). Anthropic trip...Quarterly Review · 10 min read 2025Q42025 Q4Q4 2025 marks the quarter where agentic AI moved from demo to deployment. Gemini 3 shipped in November, while the tooling layer (Claude Code, Codex, Cursor) converged on background agents that operate computers, not j...Quarterly Review · 5 min read Q32025 Q3Q3 2025 marks the quarter AI agents became operational infrastructure. Anthropic shipped Claude Opus 4.1 (August) and Claude Sonnet 4.5 (September), pushing frontier capability forward. OpenAI launched Codex as an aut...Quarterly Review · 8 min read Q22025 Q2Q2 2025 was the quarter the frontier-model race became a three-body problem. Anthropic shipped the Claude 4 family (Opus 4, Sonnet 4) on May 22, delivering a step-function improvement in sustained agentic work and ext...Quarterly Review · 7 min read Q12025 Q1Q1 2025 was a detonation quarter for AI. DeepSeek R1 proved that frontier reasoning can be replicated at a fraction of the cost with open weights, wiping ~$600B off NVIDIA's market cap in a single session. Within week...Quarterly Review · 7 min read 2024Q42024 Q4Q4 2024 was the quarter the frontier-model arms race became a full-spectrum capability war. Anthropic, OpenAI, and Google each shipped major model families within weeks of each other, while the economic layer beneath...Quarterly Review · 7 min read Q32024 Q3Q3 2024 delivered a decisive answer to the open-vs-closed debate: both sides escalated simultaneously. Meta shipped Llama 3.1 405B, the largest open-weight model to date, proving that permissive-license models can com...Quarterly Review · 8 min read Q22024 Q2Q2 2024 made multimodal AI the baseline with GPT-4o shipping free-tier vision and audio at as low as 232 ms latency (320 ms average), while Claude 3.5 Sonnet topped coding benchmarks at 1/5 the cost of Opus. Apple ent...Quarterly Review · 7 min read Q12024 Q1Q1 2024 shattered the GPT-4 monopoly as Anthropic, Google, and Mistral each shipped frontier-competitive models within weeks. The competition axis shifted from parameter counts to context windows (Gemini 1.5 Pro at 1M...Quarterly Review · 8 min read 2023Q42023 Q4Q4 2023 stress-tested AI governance and accelerated on every other axis. The OpenAI board crisis (November 17-22) demonstrated that commercial gravity overwhelms nonprofit governance structures. GPT-4 Turbo pushed con...Quarterly Review · 11 min read Q32023 Q3Q3 2023 locked in the hyperscaler-frontier lab capital structure: Amazon committed $4B to Anthropic, completing a pattern where every major frontier lab now had a cloud partner. Claude 2 shipped with 100K context, Lla...Quarterly Review · 11 min read Q22023 Q2Q2 2023 moved AI from API access to infrastructure reckoning. GPT-4 went GA, function calling landed on June 13 (resolving the core reliability problem for tool use), and the developer ecosystem shifted from "can I us...Quarterly Review · 11 min read Q12023 Q1Q1 2023 collapsed the frontier lab landscape into three meaningful positions: OpenAI (GPT-4 capability leader), Google (distribution leader playing catch-up after Bard's misfired demo), and Anthropic (safety-different...Quarterly Review · 13 min read 2022Q42022 Q4November 30, 2022 is the line. ChatGPT reached 1M users in 5 days -- not through a technical breakthrough but through a product insight: zero-friction chat interface on a marginally improved model. Google declared cod...Quarterly Review · 12 min read Q32022 Q3Q3 2022 detonated the gated-access model. Stable Diffusion's open-weight release (August 22) put frontier-quality image generation on consumer hardware, Midjourney's paid consumer model proved the economics without VC...Quarterly Review · 11 min read Q22022 Q2Q2 2022 split AI into two stories: perception and production. DALL-E 2 changed what the public thought AI could do; GitHub Copilot's GA at $10/month changed what enterprises paid AI to do. Google had technically super...Quarterly Review · 12 min read Q12022 Q1Q1 2022 rewired AI's competitive logic around two pivots: InstructGPT proved alignment is a capability multiplier (not a constraint), and Chinchilla proved compute-optimal training beats brute-force scaling. Together...Quarterly Review · 11 min read 2021Q42021 Q4Q4 2021's defining intellectual event was DeepMind publishing Gopher (280B parameters) and RETRO (7.5B + retrieval matching GPT-3) in the same week — contradicting itself on whether scale or retrieval augmentation was...Quarterly Review · 11 min read Q32021 Q3Q3 2021 proved the transformer architecture is a general-purpose substrate, not a language-specific tool. Codex demonstrated transformers on code (28.8% pass@1 on HumanEval), AlphaFold's Protein Structure Database lau...Quarterly Review · 12 min read Q22021 Q2Q2 2021 is the quarter frontier AI transitioned from a monopoly structure to a market with three credible participants. Anthropic was founded in late April and announced a $124M Series A on May 28, establishing the sa...Quarterly Review · 11 min read Q12021 Q1Q1 2021 flipped the multimodal switch with DALL-E and CLIP published simultaneously on January 5. CLIP's zero-shot transfer across 30 benchmarks was a controlled demolition of the task-specific model paradigm and the...Quarterly Review · 12 min read 2020Q42020 Q4Q4 2020 delivered three category-defining events simultaneously: AlphaFold 2 solved protein folding at CASP14 with a GDT of 92.4, proving transformers generalize beyond language to biological sequences. The Pfizer-Bio...Quarterly Review · 13 min read Q32020 Q3Q3 2020 was defined by three structural shifts: the GPT-3 API moved from research artifact to commercial product with real developer builds, prompt engineering emerged as an unnamed discipline discovered by practition...Quarterly Review · 10 min read Q22020 Q2Q2 2020 is the quarter the modern AI industry began in commercial form. GPT-3 proved the scaling thesis at 175B parameters, and the OpenAI API launch on June 11 turned AI research into a commercial product with a pric...Quarterly Review · 12 min read Q12020 Q1Q1 2020 is the quarter the scaling hypothesis went from fringe to foundation. The Kaplan et al. paper quantified power-law relationships between compute, parameters, and language model performance, giving OpenAI the c...Quarterly Review · 12 min read

Quarterly Reviews

Life Sciences / Regulatory Quarterly Reviews

2026Q22026 Q2Q2 2026 is the quarter the evidence bar for AI in regulated clinical and drug-development workflows stopped being a slogan and became an audit: FDA held the SaMD premarket gate shut against deregulatory pressure early...Quarterly Review · 14 min read Q12026 Q1Q1 2026 was defined by the QMSR taking effect (February 2), the biggest QMS overhaul in 30 years replacing Part 820 with ISO 13485 incorporation by reference. Insilico Medicine's rentosertib remained a major proof poi...Quarterly Review · 10 min read 2025Q42025 Q4Q4 2025 was the quarter where regulatory infrastructure modernized faster than the industry it governs. The UK's MHRA-NICE aligned pathway launched in October -- six months ahead of schedule -- enabling simultaneous m...Quarterly Review · 6 min read Q32025 Q3Q3 2025 is the quarter AI crossed from experimental tool to operational infrastructure in life sciences. The FDA's AI/ML clearance pace kept accelerating — later 2025 totals reached 295 devices cleared and 1,451 cumul...Quarterly Review · 8 min read Q22025 Q2Q2 2025 marked the quarter regulators stopped treating AI/ML medical devices as novelties and started building permanent infrastructure for them. The FDA's AI/ML clearance pace was on track for a record year, with PCC...Quarterly Review · 8 min read Q12025 Q1Q1 2025 was the quarter the US regulatory landscape structurally shifted. The FDA's QMSR final rule entered its active transition year, replacing the 30-year-old Part 820 QSR framework with ISO 13485 incorporation by...Quarterly Review · 7 min read 2024Q42024 Q4Q4 2024 was a quarter of regulatory milestones and pipeline validation — but also of reckoning. The FDA cleared its 1,000th AI/ML-enabled medical device, confirming algorithmic medicine as institutional reality, not e...Quarterly Review · 8 min read Q32024 Q3Q3 2024 marked the quarter when AI-driven drug discovery stopped being a thesis and became a consolidation story. The Recursion-Exscientia merger ($688M), announced August 8, was the largest AI drug discovery M&A on a...Quarterly Review · 8 min read Q22024 Q2Q2 2024 saw AlphaFold 3 redefine computational biology by expanding from protein-only to multi-molecular complex prediction, while FDA AI/ML device clearances continued accelerating through the quarter. Later full-yea...Quarterly Review · 8 min read Q12024 Q1Q1 2024 established an early transatlantic regulatory conversation on AI in medicine through EMA's reflection-paper work, while the Change Healthcare ransomware attack reframed healthcare cybersecurity as an existenti...Quarterly Review · 9 min read 2023Q42023 Q4Q4 2023 delivered convergence on three fronts: FDA's year-end AI/ML-device snapshot showed record-level clearance volume, PCCP guiding principles were published, Insilico's Phase 2a positive topline data crossed the c...Quarterly Review · 13 min read Q32023 Q3Q3 2023 exposed the structural gap between AI capability and regulatory pathway. FDA tracked toward ~300 clearances/year with cumulative total approaching 700, but zero generative AI devices were cleared. Llama 2's co...Quarterly Review · 15 min read Q22023 Q2Q2 2023 was a quarter of framework construction. FDA published PCCP draft guidance in April; the FDA/Health Canada/MHRA joint guiding principles would not arrive until October. Insilico Medicine dosed first Phase II p...Quarterly Review · 13 min read Q12023 Q1Q1 2023 delivered the adaptive AI regulatory framework: FDA published PCCP draft guidance on March 30, creating the first draftable, commentable specification for how AI/ML devices can update post-clearance. Simultane...Quarterly Review · 15 min read 2022Q42022 Q4Q4 2022 delivered three structural shifts simultaneously: FDORA signed December 29, codifying PCCP into statute and giving FDA explicit authority for adaptive AI device modification plans. AI/ML device clearances were...Quarterly Review · 16 min read Q32022 Q3Q3 2022 established the defining structural dynamic of medical AI: regulatory throughput and capital markets decoupled entirely. FDA maintained steady AI/ML clearances while biotech capital markets hit their deepest m...Quarterly Review · 15 min read Q22022 Q2Q2 2022 deepened two structural dynamics: the biotech funding winter accelerated sharply (monthly VC investment down 60%+ YoY), while FDA AI/ML device clearances continued at pace -- decoupled from capital markets. Ap...Quarterly Review · 14 min read Q12022 Q1Q1 2022 reset life sciences AI on two axes: pharma-AI partnerships escalated from exploratory to contractual (Exscientia-Sanofi at $5.2B milestones), and the digital health funding correction began separating evidence...Quarterly Review · 15 min read 2021Q42021 Q4Q4 2021 delivered the GMLP tri-agency publication (October 27) — the first concrete international convergence on AI medical device standards between FDA, Health Canada, and MHRA. FDA AI/ML device clearances approached...Quarterly Review · 17 min read Q32021 Q3Q3 2021 saw FDA's AI/ML regulatory posture harden from policy to process, with the GMLP inter-agency coordination between FDA, Health Canada, and MHRA reaching completion ahead of Q4 publication. The BMS-Exscientia op...Quarterly Review · 14 min read Q22021 Q2Q2 2021 sat inside the largest single year of biotech venture funding on record ($35B+ globally). Recursion's April IPO raised about $436M at pricing, with final gross proceeds of $501.8M including the underwriters' o...Quarterly Review · 15 min read Q12021 Q1Q1 2021 was the quarter the FDA published its AI/ML SaMD Action Plan (January 12) — the five-action framework that would govern AI medical device regulation for the next five years. The PCCP concept was introduced as...Quarterly Review · 15 min read 2020Q42020 Q4Q4 2020 delivered the first U.S. regulatory authorizations for mRNA vaccines — Pfizer-BioNTech EUA on December 11 and Moderna EUA on December 18 — establishing mRNA as a regulatory category with FDA accepting the plat...Quarterly Review · 13 min read Q32020 Q3Q3 2020 marked three simultaneous milestones: Moderna and Pfizer-BioNTech both launched 30,000+ participant Phase 3 mRNA vaccine trials on the same day (July 27), FDA's EUA pathway was stress-tested at unprecedented s...Quarterly Review · 14 min read Q22020 Q2Q2 2020 was the quarter FDA ran its most consequential regulatory experiment — the EUA pathway at production scale across diagnostics, therapeutics, and devices simultaneously. Clinical trial conduct was rewritten in...Quarterly Review · 15 min read Q12020 Q1Q1 2020 activated three simultaneous inflection points in life sciences regulation. Moderna designed mRNA-1273 in 48 hours and reached Phase I by March 16 — the fastest vaccine development sequence in recorded history...Quarterly Review · 16 min read